Leap Investments’s United Therapeutics UTHR Stock Holding History

Leap Investments’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,100	Closed	-$449K	–	568
2019 Q4	$449K	Buy	+5,100	New	+$449K	0.21%	171

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Leap Investments's UTHR Position: Q1 2020 in Review

Leap Investments sold out of United Therapeutics (UTHR) in Q1 2020, closing a stake of 5,100 shares — an estimated $449K sold.

Leap Investments first reported a position in UTHR in Q4 2019 and held it in 1 quarter. The position peaked at $449K in Q4 2019. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

Leap Investments reported no remaining United Therapeutics position as of Q1 2020 after selling out during the quarter.
Leap Investments sold 5,100 United Therapeutics shares in Q1 2020, an estimated $449K.
Leap Investments first reported a position in United Therapeutics in Q4 2019 and held it in 1 quarter.
Leap Investments's United Therapeutics position peaked at $449K in Q4 2019.
303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.